A pathway analysis of the 177 most highly enriched targets identified by RIP-seq (FDR p < 0.05, log2 enrichment ratio ≥ log21) indicated that in addition to general liver cancer metastatic pathways, the MYC pathway was significantly represented and presumably regulated by the identified MSI2 binding partners (Fig. 1E). This evidence concerns the gene MSI2 and liver cancer.